Cellics Therapeutics is pioneering drug delivery through cellular nanoparticles (CNPs). A major limitation to any gene therapy approach is the efficient and selective targeting of the genetic cargo to the cell of interest. Cellic’s two nanoplatforms, Cellular Nanosponges and the Cellular Nanoparticle drug delivery technology, harness the power of cell membranes to create CNPs for drug delivery. The cell membranes which can come from wild-type or engineered cells coat the CNPs with their intracellular contents removed. Instead, Cellic’s CNPs can be filled and used to deliver mRNA, siRNA, proteins and small molecules. Using their technology, Cellics is hoping to address serious diseases with high unmet clinical need.

Cellics Therapeutics

Founded: 2014
Location: San Diego, CA
Employee range: 11 - 50
Clinical stage: Clin0
Therapy area: MRSA pneumonia
Drug types: INF, IMM
Lead product: CTI-005
Funding: $4M grant Oct 2020

Business:

Drug notes:

About:

Jobs:

News: